ReviewYonsei medical journal2014
Molecular approach to allergy diagnosis and therapy.
Review in Yonsei medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Common Ragweed Allergy Under Global Change Linking Invasion-Driven Aeroallergen Exposure with Molecular Sensitization and Allergic Airway Disease.Life (Basel, Switzerland) · 2026Review
- Art an 3 as a candidate recombinant antigen for Artemisia pollen immunotherapy: comparative efficacy and mechanistic insights.Frontiers in medicine · 2026Article
- Interleukin-18 Receptor α Modulates the T Cell Response in Food Allergy.Allergy, asthma & immunology research · 2022Article
- Studies on HBcAg-rBlo t 5-21 Fusion Protein Vaccine That AlleviatesJournal of inflammation research · 2022Article
- Miquelianin Inhibits Allergic Responses in Mice by Suppressing CD4Antioxidants (Basel, Switzerland) · 2021Article
- China Consensus Document on Allergy Diagnostics.Allergy, asthma & immunology research · 2021Review
- A hybrid of two major Blomia tropicalis allergens as an allergy vaccine candidate.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Article
- Rational Design, Structure-Activity Relationship, and Immunogenicity of Hypoallergenic Pru p 3 Variants.Molecular nutrition & food research · 2019Article
- Validation of PROTIA™ Allergy-Q 64 Atopy® as a Specific IgE Measurement Assay for 10 Major Allergen Components.Allergy, asthma & immunology research · 2019Article
- Sensitization profile in patients with respiratory allergic diseases: differences between conventional and molecular diagnosis (a cross-sectional study).Clinical and molecular allergy : CMA · 2019Article
- The Influence of Gamma Radiation Processing on the Allergenicity of Main Pistachio Allergens.Reports of biochemistry & molecular biology · 2019Article
- Tackling Bet v 1 and associated food allergies with a single hybrid protein.The Journal of allergy and clinical immunology · 2017Article
- Structure of the Major Apple Allergen Mal d 1.Journal of agricultural and food chemistry · 2017Article
- Expression and Characterization of Functional Recombinant Bet v 1.0101 in the Chloroplast of Chlamydomonas reinhardtii.International archives of allergy and immunology · 2017Article
- Allergens of Blomia tropicalis: An Overview of Recombinant Molecules.International archives of allergy and immunology · 2017Review
- Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.International archives of allergy and immunology · 2017Review
- AllerBase: a comprehensive allergen knowledgebase.Database : the journal of biological databases and curation · 2017Article
- Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.Yonsei medical journal · 2016Article
- Clinical Significance of Component Allergens in Fagales Pollen-Sensitized Peanut Allergy in Korea.Allergy, asthma & immunology research · 2016Article
- Cross-Reactivity between Oak and Birch Pollens in Korean Tree Pollinosis.Journal of Korean medical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Presently, allergy diagnosis and therapy procedures are undergoing a transition phase in which allergen extracts are being step-by-step replaced by molecule-based products. The new developments will allow clinicians to obtain detailed information on sensitization patterns, more accurate interpretation of allergic symptoms, and thus improved patients' management. In this respect, recombinant technology has been applied to develop this new generation of molecule-based allergy products. The use of recombinant allergens allows full validation of identity, quantity, homogeneity, structure, aggregation, solubility, stability, IgE-binding and the biologic potency of the products. In contrast, such parameters are extremely difficult to assay and standardize for extract-based products. In addition to the possibility of bulk production of wild type molecules for diagnostic purposes, recombinant technology opened the possibility of developing safer and more efficacious products for allergy therapy. A number of molecule-based hypoallergenic preparations have already been successfully evaluated in clinical trials, bringing forward the next generation of allergy vaccines. In this contribution, we review the latest developments in allergen characterization, molecule-based allergy diagnosis, and the application of recombinant allergens in therapeutic setups. A comprehensive overview of clinical trials using recombinant allergens as well as synthetic peptides is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.